Cutler Group LP Vertex Pharmaceuticals Inc Call Options Transaction History

Cutler Group LP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	SELL	$273.83 - $305.53 $8.08 Million - $9.01 Million	-29,500 Reduced 98.66%	400 $2,000
Q2 2022 Aug 04, 2022	SELL	$234.96 - $292.55 $4.44 Million - $5.53 Million	-18,900 Reduced 38.73%	29,900 $2.43 Million
Q1 2022 Apr 14, 2022	BUY	$221.42 - $260.97 $5.6 Million - $6.6 Million	25,300 Added 107.66%	48,800 $2.25 Million
Q4 2021 Jan 18, 2022	BUY	$177.01 - $223.45 $3.89 Million - $4.92 Million	22,000 Added 1466.67%	23,500 $1.06 Million
Q1 2021 Apr 26, 2021	BUY	$207.02 - $241.31 $82,808 - $96,524	400 Added 36.36%	1,500 $11,000
Q3 2019 Oct 28, 2019	BUY	$166.23 - $187.09 $16,623 - $18,709	100 Added 10.0%	1,100 $16,000
Q2 2019 Aug 09, 2019	SELL	$164.61 - $190.37 $1.12 Million - $1.29 Million	-6,800 Reduced 87.18%	1,000 $21,000
Q1 2019 May 10, 2019	SELL	$163.73 - $194.7 $1.03 Million - $1.23 Million	-6,300 Reduced 44.68%	7,800 $4,000
Q4 2018 Feb 05, 2019	SELL	$151.91 - $192.21 $121,528 - $153,768	-800 Reduced 5.37%	14,100 $82,000
Q3 2018 Nov 07, 2018	SELL	$167.73 - $192.74 $83,865 - $96,370	-500 Reduced 3.25%	14,900 $291,000
Q2 2018 Aug 10, 2018	SELL	$145.72 - $169.96 $1.92 Million - $2.24 Million	-13,200 Reduced 46.15%	15,400 $235,000
Q1 2018 May 11, 2018	SELL	$151.6 - $177.13 $3.05 Million - $3.56 Million	-20,100 Reduced 41.27%	28,600 $349,000
Q4 2017 Jan 17, 2018	SELL	$137.28 - $155.55 $5.45 Million - $6.18 Million	-39,700 Reduced 44.91%	48,700 $542,000
Q3 2017 Oct 17, 2017	BUY	$148.13 - $162.24 $13.1 Million - $14.3 Million	88,400	88,400 $1.32 Million

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.